Results 191 to 200 of about 15,713 (203)

Epigenetic approach to early-onset Parkinson’s disease: low methylation status of SNCA and PARK2 promoter regions

Neurological Research, 2017
Bulent Elibol, Mehmet Zarifoglu, Ünal EGELİ   +2 more
exaly  

A Comprehensive Analysis of the Association Between SNCA Polymorphisms and the Risk of Parkinson's Disease

Frontiers in Molecular Neuroscience, 2018
Li Shu, Qiying Sun, Jifeng Guo
exaly  

Compounds and methods for reducing SNCA expression

2022
KORDASIEWICZ HOLLY, COLE TRACY A
openaire   +1 more source

Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD

Molecular Therapy, 2018
Susan K Murphy, Ornit Chiba-Falek, Boris Kantor   +2 more
exaly  

SNCA, LRRK2, MAPT polymorphisms and Parkinson's disease in Russia

Parkinsonism & Related Disorders, 2013
A, Emelyanov, P, Andoskin, A, Yakimovskii, T, Usenko, E, Nuzhnyi, M, Nikolaev, S, Pchelina   +6 more
openaire   +2 more sources

COMPOSITIONS AND METHODS FOR INHIBITING SNCA EXPRESSION

2023
BROWN BOB, DUDEK HENRYK, CHEONG SEONGMOON, WANG SHIYU, GRIM TRAVIS, COSTALES MATTHEW GUESE, JUNG MAIRE   +6 more
openaire   +1 more source

R406 and its structural analogs reduce SNCA/α-synuclein levels via autophagic degradation

Autophagy
Yu Ding, Boxun Lu, Yiyan Fei
exaly  

COMPOSITIONS AND METHODS FOR INHIBITION OF SNCA

2014
HINKLE GREGORY, BUMCROT DAVID
openaire   +1 more source

Novel Therapeutic Horizons: SNCA Targeting in Parkinson’s Disease

Biomolecules
Valentina Pirota, Alessio Maria Caramiello   +1 more
exaly  

ARTIFICIAL MICRORNAS TARGETING SNCA

ELMER BRADFORD MILLER, RAMACHANDRAN SHYAM   +1 more
openaire   +1 more source